Cantor Fitzgerald Reaffirms “Overweight” Rating for Evolus (NASDAQ:EOLS)

Cantor Fitzgerald reiterated their overweight rating on shares of Evolus (NASDAQ:EOLS) in a research report released on Monday morning, Benzinga reports.

Other research analysts also recently issued research reports about the company. Barclays boosted their price target on Evolus from $16.00 to $20.00 and gave the company an overweight rating in a report on Friday, September 13th. Needham & Company LLC restated a buy rating and set a $22.00 target price on shares of Evolus in a report on Friday, September 13th. Finally, HC Wainwright reiterated a buy rating and issued a $27.00 price target on shares of Evolus in a report on Thursday, August 1st.

Evolus Stock Down 4.0 %

Shares of Evolus stock opened at $16.22 on Monday. The company has a debt-to-equity ratio of 6.26, a quick ratio of 2.67 and a current ratio of 2.92. Evolus has a 52-week low of $7.44 and a 52-week high of $17.70. The company’s 50 day moving average price is $14.09 and its 200-day moving average price is $13.09. The stock has a market capitalization of $1.02 billion, a price-to-earnings ratio of -15.45 and a beta of 1.30.

Evolus (NASDAQ:EOLS) last released its quarterly earnings data on Wednesday, July 31st. The company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.02). The business had revenue of $66.91 million for the quarter, compared to analysts’ expectations of $65.06 million. Equities research analysts forecast that Evolus will post -0.64 EPS for the current year.

Insider Buying and Selling at Evolus

In other news, CMO Tomoko Yamagishi-Dressler sold 5,631 shares of the stock in a transaction that occurred on Friday, August 30th. The stock was sold at an average price of $15.85, for a total value of $89,251.35. Following the completion of the transaction, the chief marketing officer now owns 82,375 shares of the company’s stock, valued at approximately $1,305,643.75. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, CFO Sandra Beaver sold 3,276 shares of the business’s stock in a transaction dated Friday, September 6th. The shares were sold at an average price of $14.98, for a total transaction of $49,074.48. Following the sale, the chief financial officer now owns 148,502 shares of the company’s stock, valued at $2,224,559.96. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CMO Tomoko Yamagishi-Dressler sold 5,631 shares of the firm’s stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $15.85, for a total transaction of $89,251.35. Following the transaction, the chief marketing officer now directly owns 82,375 shares of the company’s stock, valued at approximately $1,305,643.75. The disclosure for this sale can be found here. Insiders own 6.10% of the company’s stock.

Institutional Trading of Evolus

A number of hedge funds have recently made changes to their positions in EOLS. Quest Partners LLC purchased a new position in Evolus during the second quarter valued at $43,000. Quarry LP bought a new position in Evolus in the 2nd quarter worth about $54,000. Tradition Wealth Management LLC grew its position in Evolus by 44.8% during the 4th quarter. Tradition Wealth Management LLC now owns 8,000 shares of the company’s stock valued at $84,000 after purchasing an additional 2,475 shares during the last quarter. Sierra Summit Advisors LLC purchased a new stake in Evolus during the 4th quarter valued at about $119,000. Finally, Profund Advisors LLC bought a new stake in Evolus during the 2nd quarter valued at about $130,000. 90.69% of the stock is owned by institutional investors.

About Evolus

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.